Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + apatinib
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of liposomal irinotecan and apatinib. Liposomal irinotecan is a formulation of irinotecan encapsulated in liposomes that enhances drug delivery to tumor sites through enhanced permeability and retention (EPR) effects. Apatinib is a selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor that inhibits tumor angiogenesis. This combination has been investigated in clinical trials for various advanced solid tumors, often in combination with immunotherapy (camrelizumab) and radiotherapy.
- Brand names
- AiTanOnivydeDuoenda
- Other names
- irinotecan liposomal + apatinib
02
Targets
TOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on liposomal irinotecan + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + apatinib.